The Apex Times
Above the Noise
Business Wire
BusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex Times
Back to front
Eli Lilly stock rises premarket as new retatrutide trial data show benefits beyond weight loss
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 8, 1:01 PM EDT

Eli Lilly stock rises premarket as new retatrutide trial data show benefits beyond weight loss

Investors reacted Monday to additional Phase 3 results for retatrutide, Eli Lilly’s investigational triple-hormone obesity drug, including improvements in knee osteoarthritis pain, obstructive sleep apnea and type 2 diabetes markers.

By The Apex Times Newsroom1 min readAI-assisted Apex article

Eli Lilly’s shares jumped in premarket trading Monday after the company disclosed additional Phase 3 data for retatrutide, an investigational next-generation obesity drug, showing benefits in several obesity-related conditions. Reuters reported the stock was up about 4% before the opening bell on June 8, 2026, as analysts weighed what the new results could mean for Lilly’s position in an increasingly crowded obesity market.

Lilly’s announcement, made Saturday and presented at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, focused on two pivotal studies within its retatrutide development program. In the TRIUMPH-1 program, retatrutide met primary endpoints at 80 weeks not only for weight loss in adults with obesity, but also in “basket” studies aimed at knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea. “Obesity drives more than 200 downstream diseases,” said Dr. Ania Jastreboff, who led the studies, adding that obesity-related complications have often been treated in “silos.”

Why It Matters

  • If regulators eventually approve retatrutide, Lilly is positioning it as a drug that targets multiple downstream complications of obesity rather than weight alone.
  • The results could influence how clinicians compare retatrutide with established therapies, including Lilly’s own Zepbound and competitor GLP-1-based drugs, especially if tolerability and dosing are competitive.
  • The trial endpoints extend beyond cardiometabolic risk factors to symptom-focused outcomes like knee pain and sleep apnea severity, broadening potential use cases.
  • Market pricing for next-generation obesity drugs is increasingly tied to whether late-stage data suggest durable benefit across comorbidities.
  • Further investor attention will likely shift to the next readouts in Lilly’s retatrutide program and any regulatory milestones that follow.

Sources

Key Facts

  • Eli Lilly said Saturday that new Phase 3 retatrutide results showed improvements in obesity-related conditions in two pivotal trials.
  • In TRIUMPH-1 at 80 weeks, retatrutide 12 mg produced average weight loss of 70.3 pounds (28.3%), with 65.3% of participants reaching a BMI below 30.
  • In the same trial, Lilly reported reductions up to 4.3 points (73.1%) in knee osteoarthritis pain and up to 36.1 events per hour (60.6%) in obstructive sleep apnea severity on retatrutide.
  • In TRANSCEND-T2D-1 at 40 weeks, retatrutide achieved A1C reductions of up to 2.0% from a baseline of 7.9% and weight loss of up to 36.6 pounds (16.8%).
  • Reuters said Lilly shares were up about 4% premarket Monday, citing the new data and investor expectations for Lilly’s lead in the obesity market.
  • Lilly said retatrutide is an investigational once-weekly triple hormone receptor agonist (GIP, GLP-1 and glucagon) and is being studied across multiple Phase 3 obesity and diabetes-related indications.

Healthcare Related

Eli Lilly stock rises premarket as new retatrutide trial data show benefits beyond weight loss | The Apex Times